Voluntary announcement - risvutatug rezetecan for injection (HS-20093) for osteosarcoma included in priority review and approval procedure of the nmpa
Filed with HKEX · Stock code 3692 · · 1 page · English
Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 3692) VOLUNTARY ANNOUNCEMENT RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR OSTEOSARCOMA INCLUDED IN PRIORITY REVIEW AND APPROVAL PROCEDURE OF THE NMPA The board of directors (the “Board”) of Hansoh Pharmaceutical Group Company Limited (the “Company” and together with
Hansoh Pharmaceutical Group Company Limited on 6ix
Earlier from Hansoh Pharmaceutical
- Hansoh Pharmaceutical Group: Pharma announces pivotal phase 3 clinical trial of HS-10374 in the treatment of adults with moderate-to-severe plaque psoriasis met the co-primary endpoints
- Voluntary announcement - the phase iii clinical study of HS-10374 in the treatment of moderate-to-severe plaque psoriasis has met the co-primary endpoints
- Voluntary announcement - the clinical trial approval for HS-20197 for injection issued by the national medical products administration
- Hansoh Pharmaceutical Group: Wclc 2026 | hansoh pharma announces proffered oral presentation of phase i study data of HS-10370 combined with adebrelimab and chemotherapy in advanced kras G12C-mutated nsclc
- Hansoh Pharmaceutical Group: 2026 Wclc | hansoh pharma announces interim results from phase 3 artemis-008 study of risvutatug rezetecan (HS-20093) in patients with relapsed small cell lung cancer
Later from Hansoh Pharmaceutical
- Interim report 2026
- Notification letter to registered shareholders and reply form
- Notification letter to non-registered holders and request form
- Voluntary announcement - biologics license application of risvutatug rezetecan for injection (HS-20093) for osteosarcoma accepted by the nmpa
- Voluntary announcement - update on the marketing authorization status of aumolertinib in the EU
Follow Hansoh Pharmaceutical into a list and get an email when it puts out news.
Follow Hansoh Pharmaceutical